Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25045333 | 0.92 | PDE7A (0.40) | PDE7AHSD17B10ADORA2A | |
| SCHEMBL8341378 | 0.88 | PARP2 (0.42) | PDE7ALMNAALDH1A1TP53MAPT | |
| SCHEMBL14490260 | 0.85 | PKM (0.39) | PDE7ALMNATP53ADORA2A | |
| SCHEMBL2855878 | 0.83 | TP53 (0.40) | PDE7ATP53 | |
| SCHEMBL852749 | 0.83 | MAPK1 (0.40) | PDE7AMAPK1 | |
| SCHEMBL852748 | 0.83 | MAPK1 (0.40) | PDE7AMAPK1 | |
| SCHEMBL14900009 | 0.82 | CHRM2 (0.38) | PDE7A | |
| Hydrochloric Acid SCHEMBL27993842 | 0.82 | MAPK1 (0.39) | PDE7AMAPK1 | |
| SCHEMBL15919806 | 0.81 | LMNA (0.36) | PDE7ALMNAALDH1A1TP53MAPT | |
| SCHEMBL14826661 | 0.81 | LMNA (0.36) | PDE7ALMNAALDH1A1TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190307776-A1 | AZA-SUBSTITUTED INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2019-10-10 | — | — | US | disclosed |
| US-20190135857-A1 | TRITERPENOID INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-09 | — | — | US | disclosed |
| US-9969767-B2 | Oxolupene derivatives | VIIV Healthcare UK (No.5) Limited (GB) | 2018-05-15 | — | — | US | disclosed |
| US-9969767-B2 | Oxolupene derivatives | VIIV Healthcare UK (No.5) Limited (GB) | 2018-05-15 | — | — | US | disclosed |
| US-20170334946-A1 | OXOLUPENE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2017-11-23 | — | — | US | disclosed |
| US-20170334946-A1 | OXOLUPENE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2017-11-23 | — | — | US | disclosed |
| EP-2670765-B1 | C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO 4) LTD (GB) | 2017-10-18 | — | — | EP | disclosed |
| EP-2814834-B1 | C-3 CYCLOALKENYL TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO 5) LTD (GB) | 2017-09-13 | — | — | EP | disclosed |
| US-20160151387-A1 | COMPOSITIONS HAVING C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20160151387-A1 | COMPOSITIONS HAVING C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20140243298-A1 | C-3 ALKYL AND ALKENYL MODIFIED BETULINIC ACID DERIVATIVES | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2014-08-28 | — | — | US | disclosed |
| WO-2014130810-A1 | C-3 ALKYL AND ALKENYL MODIFIED BETULINIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF HIV | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-28 | — | — | WO | disclosed |
| WO-2014123889-A1 | C-19 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-14 | — | — | WO | disclosed |
| US-20140221361-A1 | C-19 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2014-08-07 | — | — | US | disclosed |
| WO-2013123019-A1 | C-3 CYCLOALKENYL TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-22 | — | — | WO | disclosed |
| US-20130210787-A1 | C-3 CYCLOALKENYL TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210787-A1 | C-3 CYCLOALKENYL TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130035318-A1 | C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2013-02-07 | — | — | US | disclosed |
| US-20130035318-A1 | C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2013-02-07 | — | — | US | disclosed |
| WO-2012106190-A1 | C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135857-A1 | TRITERPENOID INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | CYP51A1, LSS, CCNI | PDE7A 1908/4885LMNA 3402/4885ALDH1A1 3029/4885 |
| US-20140243298-A1 | C-3 ALKYL AND ALKENYL MODIFIED BETULINIC ACID DERIVATIVES | BET1, TMPO, PGGT1B | PDE7A 3079/4885LMNA 1045/4885ALDH1A1 1992/4885 |
| US-20170334946-A1 | OXOLUPENE DERIVATIVES | BET1, CYP51A1, PGGT1B | PDE7A 2633/4885LMNA 3554/4885ALDH1A1 1759/4885 |
| US-20190307776-A1 | AZA-SUBSTITUTED INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | CYP51A1, TYMP, TYMS | PDE7A 318/4885LMNA 4074/4885ALDH1A1 1637/4885 |
| US-20130035318-A1 | C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, UGT2B17, CDK17 | PDE7A 753/4885LMNA 2166/4885ALDH1A1 1833/4885 |
| US-20140221361-A1 | C-19 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, UGT2B17, CYP4A22 | PDE7A 1172/4885LMNA 2635/4885ALDH1A1 2002/4885 |
| US-20160151387-A1 | COMPOSITIONS HAVING C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, UGT2B17, HSD17B7 | PDE7A 648/4885LMNA 2154/4885ALDH1A1 2193/4885 |
| US-20130210787-A1 | C-3 CYCLOALKENYL TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, ZC3HAV1, CYP8B1 | PDE7A 1500/4885LMNA 1522/4885ALDH1A1 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.